Results 21 to 30 of about 6,146 (182)

1. Effect of empagliflozin on cardiovascular death in subgroups by age: Results from EMPA-REG outcome

Journal of the Saudi Heart Association, 2017
Clinical Research. Presentation type: Poster Presentation. Introduction: Empagliflozin is a potent and selective SGLT2-I used in the treatment of T2DM.
Mahmoud Elrouby, Elvira Toural
doaj   +1 more source

Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure

ESC Heart Failure, 2022
Aims In this prospective, placebo‐controlled, double‐blind, exploratory study, we examined early and more delayed effects of empagliflozin treatment on haemodynamic parameters (primary endpoint: cardiac output) and kidney function including parameters of
Kirsten Thiele, Matthias Rau, Niels‐Ulrik Korbinian Hartmann, Marcus Möller, Julia Möllmann, Joachim Jankowski, András P. Keszei, Michael Böhm, Jürgen Floege, Nikolaus Marx, Michael Lehrke   +10 more
doaj   +1 more source

Empagliflozin Attenuates Neointima Formation After Arterial Injury and Inhibits Smooth Muscle Cell Proliferation and Migration by Suppressing Platelet‐Derived Growth Factor–Related Signaling

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce cardiovascular events. However, the precise mechanisms beyond glycemic control are not fully understood.
Gwo‐Jyh Chang, Wei‐Jan Chen, Yu‐Juei Hsu, Ying‐Hwa Chen   +3 more
doaj   +1 more source

Empagliflozin attenuates cardiac microvascular ischemia/reperfusion through activating the AMPKα1/ULK1/FUNDC1/mitophagy pathway

Redox Biology, 2022
Mitophagy preserves microvascular structure and function during myocardial ischemia/reperfusion (I/R) injury. Empagliflozin, an anti-diabetes drug, may also protect mitochondria.
Chen Cai, Zhongzhou Guo, Xing Chang, Ziying Li, Feng Wu, Jing He, Tiantian Cao, Kangrong Wang, Nengxian Shi, Hao Zhou, Sam Toan, David Muid, Ying Tan   +12 more
doaj   +1 more source

Empagliflozin Is Not Renoprotective in Non-Diabetic Rat Models of Chronic Kidney Disease

Biomedicines, 2022
Gliflozins (sodium-glucose transporter-2 inhibitors) exhibited renoprotective effects not only in diabetic but also in non-diabetic patients with chronic kidney disease (CKD). Controversial results were reported in experimental non-diabetic models of CKD.
Silvie Hojná, Zoe Kotsaridou, Zdeňka Vaňourková, Hana Rauchová, Michal Behuliak, Petr Kujal, Michaela Kadlecová, Josef Zicha, Ivana Vaněčková   +8 more
doaj   +1 more source

Empagliflozin improves renal ischemia–reperfusion injury by reducing inflammation and enhancing mitochondrial fusion through AMPK–OPA1 pathway promotion

Cellular & Molecular Biology Letters, 2023
Background Renal ischemia–reperfusion injury (IRI) is one reason for renal transplantation failure. Recent studies have shown that mitochondrial dynamics is closely related to IRI, and that inhibition or reversal of mitochondrial division protects organs
Wenbo Yang, Xiaoli Li, Liujie He, Shuyang Zhu, Shicong Lai, Xiaopeng Zhang, Zixiong Huang, Biyue Yu, Chunping Cui, Qiang Wang   +9 more
doaj   +1 more source

Decoding empagliflozin’s molecular mechanism of action in heart failure with preserved ejection fraction using artificial intelligence

Scientific Reports, 2021
The use of sodium-glucose co-transporter 2 inhibitors to treat heart failure with preserved ejection fraction (HFpEF) is under investigation in ongoing clinical trials, but the exact mechanism of action is unclear.
Antoni Bayes-Genis, Oriol Iborra-Egea, Giosafat Spitaleri, Mar Domingo, Elena Revuelta-López, Pau Codina, Germán Cediel, Evelyn Santiago-Vacas, Adriana Cserkóová, Domingo Pascual-Figal, Julio Núñez, Josep Lupón   +11 more
doaj   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Risk of Autoimmune Rheumatic Diseases

Arthritis &Rheumatology, Accepted Article.
Objective GLP‐1 receptor agonists (GLP‐1RAs) and SGLT2 inhibitors (SGLT2is) facilitate weight loss and exhibit immunomodulatory effects, but their impact on the risk of developing autoimmune rheumatic diseases (ARDs) is unclear. We compared ARD incidence following initiation of GLP‐1RAs, or SGLT2is, vs.
Derin Karacabeyli, Diane Lacaille, Na Lu, Hui Xie, J. Antonio Aviña‐Zubieta   +4 more
wiley   +1 more source

Empagliflozin Alleviates Carfilzomib-Induced Cardiotoxicity in Mice by Modulating Oxidative Stress, Inflammatory Response, Endoplasmic Reticulum Stress, and Autophagy

Antioxidants
Carfilzomib is an irreversible proteasome inhibitor used for multiple myeloma patients. However, carfilzomib treatment is associated with cardiovascular complications.
Mina Y. George, Mohamed S. Dabour, Eman Rashad, Beshay N. Zordoky   +3 more
doaj   +1 more source

The sodium–glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats

Cardiovascular Diabetology, 2019
Background Sodium glucose co-transporter 2 inhibitor (SGLT2i), a new class of anti-diabetic drugs acting on inhibiting glucose resorption by kidneys, is shown beneficial in reduction of heart failure hospitalization and cardiovascular mortality.
Hsiang-Chun Lee, Yi-Lin Shiou, Shih-Jie Jhuo, Chia-Yuan Chang, Po-Len Liu, Wun-Jyun Jhuang, Zen-Kong Dai, Wei-Yu Chen, Yun-Fang Chen, An-Sheng Lee   +9 more
doaj   +1 more source